[ET Net News Agency, 24 May 2021] Daiwa Research cut its target price for JD Health
International (06618) to HK$130.5 from HK$148.2 but upgraded its rating to "outperform"
from "hold".
The research house highlighted JDH's strong capability in supply chain and digital
marketing, and its determination in strengthening online healthcare services. By
leveraging JD Group's extensive supply chain, national fulfillment networks and DNA in
direct sales, JDH has built a robust supply chain infrastructure for players along the
healthcare value chain.
Daiwa raised its 2021-22 revenue by 5-7% on fast traffic growth and strong growth of the
digital marketing business. (KL)